{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:56:12Z","timestamp":1775868972731,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["Study 214886"],"award-info":[{"award-number":["Study 214886"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02234-x","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T05:02:58Z","timestamp":1658293378000},"page":"4961-5010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Efficacy of Umeclidinium\/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Afisi S.","family":"Ismaila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Haeussler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandrosz","family":"Czira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita","family":"Tongbram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Malmen\u00e4s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Nassim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"\u017divkovi\u0107-Gojovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunrong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Compton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M. G.","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"2234_CR1","unstructured":"Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for prevention, diagnosis and management of COPD. 2022. https:\/\/goldcopd.org\/wp-content\/uploads\/2021\/11\/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed December 2021."},{"key":"2234_CR2","unstructured":"National Institute of Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2018. https:\/\/www.nice.org.uk\/guidance\/ng115\/resources\/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245. Accessed July 2021."},{"key":"2234_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:e56\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"2234_CR4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149:1181\u201396.","journal-title":"Chest"},{"key":"2234_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","volume":"71","author":"Y Oba","year":"2016","unstructured":"Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15\u201325.","journal-title":"Thorax"},{"key":"2234_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41030-017-0048-0","volume":"3","author":"KYJ Sion","year":"2017","unstructured":"Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila AS. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3:297\u2013316.","journal-title":"Pulm Ther"},{"key":"2234_CR7","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.2147\/COPD.S173472","volume":"13","author":"MIA Aziz","year":"2018","unstructured":"Aziz MIA, Tan LE, Wu DB, et al. Comparative efficacy of inhaled medications (ICS\/LABA, LAMA, LAMA\/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3203\u201331.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41533-018-0099-1","volume":"28","author":"MK Han","year":"2018","unstructured":"Han MK, Ray R, Foo J, Morel C, Hahn B. Systematic literature review and meta-analysis of US-approved LAMA\/LABA therapies versus tiotropium in moderate-to-severe COPD. NPJ Prim Care Respir Med. 2018;28:32.","journal-title":"NPJ Prim Care Respir Med"},{"key":"2234_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2147\/COPD.S130482","volume":"12","author":"GJ Rodrigo","year":"2017","unstructured":"Rodrigo GJ, Price D, Anzueto A, et al. LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907\u201322.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR10","unstructured":"Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021): Cochrane; 2021. www.training.cochrane.org\/handbook."},{"key":"2234_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"2234_CR12","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1002\/sim.1566","volume":"22","author":"AE Ades","year":"2003","unstructured":"Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med. 2003;22:2995\u20133016.","journal-title":"Stat Med"},{"key":"2234_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897\u2013900.","journal-title":"BMJ"},{"key":"2234_CR14","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105\u201324.","journal-title":"Stat Med"},{"key":"2234_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3:312\u201324.","journal-title":"Res Synth Methods"},{"key":"2234_CR16","unstructured":"R\u00fccker G, Krahn U, K\u00f6nig J, Efthimiou O, Schwarzer G. Package 'netmeta': network meta-analysis using frequentist methods; 2022. https:\/\/cran.r-project.org\/web\/packages\/netmeta\/netmeta.pdf. Accessed December 2021."},{"key":"2234_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111\u201324.","journal-title":"COPD"},{"key":"2234_CR18","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484\u201394.","journal-title":"Eur Respir J"},{"key":"2234_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur Respir J. 2015;45:969\u201379.","journal-title":"Eur Respir J"},{"key":"2234_CR20","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","volume":"107","author":"JF Donohue","year":"2013","unstructured":"Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD. Respir Med. 2013;107:1538\u201346.","journal-title":"Respir Med"},{"key":"2234_CR21","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","volume":"33","author":"MR Maleki-Yazdi","year":"2017","unstructured":"Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33:2188\u201399.","journal-title":"Adv Ther"},{"key":"2234_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","volume":"20","author":"F Maltais","year":"2019","unstructured":"Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20:238.","journal-title":"Respir Res"},{"key":"2234_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/COPD.S252354","volume":"15","author":"T Plate","year":"2020","unstructured":"Plate T, Friedrich FW, Beier J. Effectiveness and tolerability of LABA\/LAMA fixed-dose combinations aclidinium\/formoterol, glycopyrronium\/indacaterol and umeclidinium\/vilanterol in the treatment of COPD in daily practice\u2014results of the non-interventional DETECT study. Int J Chron Obstruct Pulmon Dis. 2020;15:1335\u201347.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR24","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s12325-019-01015-3","volume":"36","author":"F Maltais","year":"2019","unstructured":"Maltais F, Ferguson GT, Feldman GJ, et al. A randomized, double-blind, double-dummy study of glycopyrrolate\/formoterol fumarate metered dose inhaler relative to umeclidinium\/vilanterol dry powder inhaler in COPD. Adv Ther. 2019;36:2434\u201349.","journal-title":"Adv Ther"},{"key":"2234_CR25","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s12325-017-0626-4","volume":"34","author":"GJ Feldman","year":"2017","unstructured":"Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium\/vilanterol and tiotropium\/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34:2518\u201333.","journal-title":"Adv Ther"},{"key":"2234_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101841","volume":"59","author":"P Rogliani","year":"2019","unstructured":"Rogliani P, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;59: 101841.","journal-title":"Pulm Pharmacol Ther"},{"key":"2234_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pupt.2017.12.005","volume":"49","author":"JF Donohue","year":"2018","unstructured":"Donohue JF, Jones PW, Bartels C, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11\u20139.","journal-title":"Pulm Pharmacol Ther"},{"key":"2234_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/15412555.2018.1445213","volume":"15","author":"K Kostikas","year":"2018","unstructured":"Kostikas K, Aalamian-Mattheis M, Pagano VA, et al. Early changes in eDiary COPD symptoms predict clinically relevant treatment response at 12 weeks: analysis from the CRYSTAL study. COPD. 2018;15:185\u201391.","journal-title":"COPD"},{"key":"2234_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/COPD.S116719","volume":"12","author":"D Price","year":"2017","unstructured":"Price D, Ostrem A, Thomas M, Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes\u2014a review. Int J Chron Obstruct Pulmon Dis. 2017;12:141\u201368.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR30","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2147\/COPD.S171835","volume":"13","author":"BJ Lipworth","year":"2018","unstructured":"Lipworth BJ, Collier DJ, Gon Y, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018;13:2969\u201384.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR31","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109:1312\u20139.","journal-title":"Respir Med"},{"key":"2234_CR32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","volume":"102","author":"C Vogelmeier","year":"2008","unstructured":"Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511\u201320.","journal-title":"Respir Med"},{"key":"2234_CR33","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","volume":"108","author":"MR Maleki-Yazdi","year":"2014","unstructured":"Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752\u201360.","journal-title":"Respir Med"},{"key":"2234_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","volume":"6","author":"PMA Calverley","year":"2018","unstructured":"Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6:337\u201344.","journal-title":"Lancet Respir Med"},{"key":"2234_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00408-017-0055-9","volume":"195","author":"E Kerwin","year":"2017","unstructured":"Kerwin E, Ferguson GT, Sanjar S, et al. Dual bronchodilation with indacaterol maleate\/glycopyrronium bromide compared with umeclidinium bromide\/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studies. Lung. 2017;195:739\u201347.","journal-title":"Lung"},{"key":"2234_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40268-016-0131-2","volume":"16","author":"C Kalberg","year":"2016","unstructured":"Kalberg C, O\u2019Dell D, Galkin D, Newlands A, Fahy WA. Dual bronchodilator therapy with umeclidinium\/vilanterol versus tiotropium plus indacaterol in chronic obstructive pulmonary disease: a randomized controlled trial. Drugs R D. 2016;16:217\u201327.","journal-title":"Drugs R D"},{"key":"2234_CR37","doi-asserted-by":"publisher","unstructured":"Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L. Effects of umeclidinium\/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Res. 2018;4. https:\/\/doi.org\/10.1183\/23120541.00073-2017.","DOI":"10.1183\/23120541.00073-2017"},{"key":"2234_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","volume":"67","author":"DA Mahler","year":"2012","unstructured":"Mahler DA, D\u2019Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67:781\u20138.","journal-title":"Thorax"},{"key":"2234_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/COPD.S51592","volume":"9","author":"W Vincken","year":"2014","unstructured":"Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014;9:215\u201328.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199\u2013209.","journal-title":"Lancet Respir Med"},{"key":"2234_CR41","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1183\/13993003.00216-2016","volume":"48","author":"C Vogelmeier","year":"2016","unstructured":"Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium\/formoterol versus salmeterol\/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48:1030\u20139.","journal-title":"Eur Respir J"},{"key":"2234_CR42","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222\u201334.","journal-title":"N Engl J Med"},{"key":"2234_CR43","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/COPD.S189138","volume":"14","author":"S Sethi","year":"2019","unstructured":"Sethi S, Kerwin E, Watz H, et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium\/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:667\u201382.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","volume":"15","author":"AD D'Urzo","year":"2014","unstructured":"D\u2019Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.","journal-title":"Respir Res"},{"key":"2234_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.rmed.2017.02.008","volume":"125","author":"A D'Urzo","year":"2017","unstructured":"D\u2019Urzo A, Rennard S, Kerwin E, et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium\/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med. 2017;125:39\u201348.","journal-title":"Respir Med"},{"key":"2234_CR46","first-page":"716","volume":"3","author":"GT Ferguson","year":"2016","unstructured":"Ferguson GT, Taylor AF, Thach C, et al. Long-term maintenance bronchodilation with indacaterol\/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT\u00a03 study. Chronic Obstr Pulm Dis. 2016;3:716\u201328.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"2234_CR47","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1164\/rccm.201505-1048OC","volume":"192","author":"DA Mahler","year":"2015","unstructured":"Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol\/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:1068\u201379.","journal-title":"Am J Respir Crit Care Med"},{"key":"2234_CR48","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2147\/COPD.S102962","volume":"11","author":"TM Siler","year":"2016","unstructured":"Siler TM, Donald AC, O\u2019Dell D, Church A, Fahy WA. A randomized, parallel-group study to evaluate the efficacy of umeclidinium\/vilanterol 62.5\/25 mug on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/COPD.S119032","volume":"12","author":"EM Kerwin","year":"2017","unstructured":"Kerwin EM, Kalberg CJ, Galkin DV, et al. Umeclidinium\/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. Int J Chron Obstruct Pulmon Dis. 2017;12:745\u201355.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.rmed.2016.05.007","volume":"116","author":"JF Donohue","year":"2016","unstructured":"Donohue JF, Soong W, Wu X, Shrestha P, Lei A. Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD. Respir Med. 2016;116:41\u20138.","journal-title":"Respir Med"},{"key":"2234_CR51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chest.2016.11.028","volume":"151","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate\/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151:340\u201357.","journal-title":"Chest"},{"key":"2234_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/thoraxjnl-2014-206345","volume":"70","author":"R Buhl","year":"2015","unstructured":"Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015;70:311\u20139.","journal-title":"Thorax"},{"key":"2234_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/15412550902724073","volume":"6","author":"DP Tashkin","year":"2009","unstructured":"Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6:17\u201325.","journal-title":"COPD"},{"key":"2234_CR54","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/resp.13374","volume":"23","author":"PA Frith","year":"2018","unstructured":"Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol\/glycopyrronium from salmeterol\/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology. 2018;23:1152\u20139.","journal-title":"Respirology"},{"key":"2234_CR55","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1378\/chest.13-1579","volume":"145","author":"B Celli","year":"2014","unstructured":"Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145:981\u201391.","journal-title":"Chest"},{"key":"2234_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12890-015-0092-1","volume":"15","author":"D Singh","year":"2015","unstructured":"Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15:91.","journal-title":"BMC Pulm Med"},{"key":"2234_CR57","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","volume":"109","author":"JF Donohue","year":"2015","unstructured":"Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109:870\u201381.","journal-title":"Respir Med"},{"key":"2234_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","volume":"1","author":"CF Vogelmeier","year":"2013","unstructured":"Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51\u201360.","journal-title":"Lancet Respir Med"},{"key":"2234_CR59","first-page":"1015","volume":"10","author":"N Zhong","year":"2015","unstructured":"Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol\/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015\u201326.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.pupt.2014.08.002","volume":"30","author":"M Hoshino","year":"2015","unstructured":"Hoshino M, Ohtawa J, Akitsu K. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair((R)) in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;30:128\u201333.","journal-title":"Pulm Pharmacol Ther"},{"key":"2234_CR61","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2466-14-178","volume":"14","author":"D Singh","year":"2014","unstructured":"Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.","journal-title":"BMC Pulm Med"},{"key":"2234_CR62","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2147\/COPD.S72482","volume":"9","author":"R ZuWallack","year":"2014","unstructured":"ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat(\u00ae) and tiotropium HandiHaler(\u00ae) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133\u201344.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2234_CR63","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.rmed.2013.05.016","volume":"107","author":"R Dahl","year":"2013","unstructured":"Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med. 2013;107:1558\u201367.","journal-title":"Respir Med"}],"updated-by":[{"DOI":"10.1007\/s12325-022-02288-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02234-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:42:12Z","timestamp":1664559732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02234-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02234-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-022-02288-x","URL":"https:\/\/doi.org\/10.1007\/s12325-022-02288-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}